Methods for prevention and treatment of inflammation using anti-chemokine antibodies

Abstract

It is possible to inhibit inflammatory processes by administration of antibodies to chemokines. Identification of chemokines which are over-produced makes it possible to block specific chemokine activity using antibodies to the over-expressed chemokines.

What is claimed is: 
     
         1 . A method of inhibiting inflammation by administration of a antibodies or antigen-binding fragments which binds at least one mammalian chemokine chosen from CXCL9, CXCL10, CXCL11, CCRL1, CCRL2, CCR5, CCL1, CCL2, CCL3, CCL4, CCL4L1, CCL5, CCL7, CCL8, CCL14-1, CCL14-2, CCL14-3, CCL15-9, CCL16, CCL19, CCL23-1, CCL23-2, CCL24, CCL26, CCR6, CCL20, CCL25, CCL25-1, CCL25-2, and CCR10 by administration to a mammal in need of anti-inflammatory intervention, of an inflammation-inhibiting effective amount of said antibodies or antigen-binding fragments in a pharmaceutically acceptable carrier. 
     
     
         2 . The method of  claim 1  wherein the carrier is a liquid. 
     
     
         3 . The method of  claim 1  wherein said mammal is human. 
     
     
         4 . The method of  claim 1  wherein the carrier is a solid support. 
     
     
         5 . The method of  claim 1  wherein said antibodies or antigen-binding fragments are derived from a human, humanized, chimeric antibody. 
     
     
         6 . The method of  claim 1  wherein said antibodies or antigen binding fragments are administered directly to tissue showing an inflammatory response tissue. 
     
     
         7 . A method of treating a mammal with inflammatory disease by the steps of:
 1) exposing tissues from said mammal to differing antibodies which bind to specific chemokines;   2) identifying level of expression of each chemokine based on binding of the each of the differing antibodies; and   3) administering to said mammal those specific antibodies which bind to the over-expressed chemokines.   
     
     
         8 . The method of  claim 7 , wherein, in step 3, the antibodies are administered directly to the affected tissue. 
     
     
         9 . The method of  claim 7  wherein, in step 3, the antibodies are administered parenterally. 
     
     
         10 . The method of  claim 7  wherein the antibodies are administered in a liquid carrier. 
     
     
         11 . The method of  claim 7  wherein the antibodies are administered on a solid support. 
     
     
         12 . A method of treating a mammal with inflammatory disease by the steps of: 1) identifying the level of particular chemokines using PCR, 2) administering to said mammal those specific antibodies which bind to the over-expressed chemokines in a pharmaceutically acceptable carrier. 
     
     
         13 . The method of  claim 12  wherein the antibodies are administered directly to the affected tissue. 
     
     
         14 . The method of  claim 12 , wherein the antibodies are administered systemically. 
     
     
         15 . The method of  claim 12 , wherein the antibodies are administered on a solid support.